Maple Capital Management Inc. has reduced its stake in Medtronic PLC by 5.2% during the first quarter, selling 165 shares in the process. The move leaves the institutional investor with 3,015 shares of the medical device giant, now valued at approximately $271,000.

Medtronic has received a fresh boost in projected earnings for FY2026. According to a recent report by Leerink Partnrs, the medical technology leader is expected to post higher-than-previously-forecasted earnings per share in the upcoming financial year.